218. Network meta-analysis comparing relatively selective COX-2 inhibitors versus coxibs for the prevention of NSAID-induced gastrointestinal injury / M. Yang, H.T. Wang, M. Zhao [et al.] // Medicine (Baltimore). - 2015, Oct. - Vol. 94(40). - P. 1592.

219. Niv Y. H. pylori/NSAID-negative peptic ulcer-the mucin theory / Y. Niv // Med Hypotheses. - 2010, Nov. - Vol. 75(5). - P. 433-435.

220. NSAID-gastroenteropathy: new aspects of pathogenesis and prevention / R.W. Blackler, B. Gemici, A. Manko [et al.] // Curr Opin Pharmacol. - 2014, Dec. - N 19. - P. 11-16.

221. Ohba R. Pathogenesis and risk factors for gastric cancer after Helicobacter pylori eradication / R. Ohba R, K. Iijima // World J Gastrointest Oncol. - 2016, Sep. - Vol. 8(9). - P. 663-672.

222. Ohkusa T. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated / T. Ohkusa // Ann Intern. Med. - 2010. - Vol. 134. - P. 380-386.

223. Olaofe O.O. A review of the clinicopathologic characteristics of intestinal metaplasia in gastric mucosal biopsies / O.O. Olaofe, D. Sabageh, A.O. Komolafe // Pan Afr Med J. - 2016, Mar. - N 23. - P. 77.

224. OLGA and OLGIM stage distribution according to age and Helicobacter pylori status in the Korean population / J.H. Nam, I.J. Choi, M.C. Kook [et al.] // Helicobacter. - 2014, Apr. - Vol. 19(2). - P.81-89.

225. OLGA staging for gastritis: a tutorial / M. Rugge, P. Correa, F. Di Mario [et al.] // Dig. Liver Dis. - 2008, Aug. - Vol. 40(8). - P. 650-658.

226. Only live Helicobacter pylori is capable of caspase-3 dependent apoptosis induction in gastric mucosa epithelial cells / P. Pierzchalski, J. Pytko-Polonczyk, J. Jaworek [ et al.] //J. Physiol Pharmacol. - 2009, Dec. - Vol. 60(4). - P. 119-128.

227. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment / M. Rugge, M. Fassan, M. Pizzi [et al.] // World J Gastroenterol. - 2011, Nov. - Vol. 17(41). - P. 4596-4601.

228. Patient priorities in osteoarthritis and comorbid conditions: a secondary analysis of qualitative data / S. Cheraghi-Sohi, P. Bower , A. Kennedy [et al.] // Arthritis Care Res (Hoboken). - 2013, Jun. - Vol. 65(6). - P. 920-927.

229. Pepsinogens to distinguish patients with gastric intestinal metaplasia and Helicobacter pylori infection among populations at risk for gastric cancer / V. De Re, E. Orzes, V. Canzonieri [et al.] // Clin Transl Gastroenterol. - 2016, Jul. - Vol. 7(7). - P. 183.

230. Polydorides A.D. Pathology and differential diagnosis of chronic, noninfectious gastritis / A.D. Polydorides // Semin Diagn Pathol. - 2014, Mar. - Vol. 31(2). - P. 114-123.

231. Precancerous histopathologic lesions of upper gastrointestinal tract among dyspeptic patients upon endoscopic evaluations // G. Abangah, A. Rahmani, M.R. Hafezi-Ahmadi [et al.] // J Gastrointest Cancer - 2016, Mar. - Vol. 47(1). - P. 1-7.

232. Precancerous lesions in the stomach: from biology to clinical patient management / M. Rugge, L.G. Capelle, R. Cappellesso [et al.] // Best Pract Res Clin Gastroenterol. - 2013, Apr. - Vol. 27(2). - P. 205-223.

233. Prevalence of gastric precancerous conditions: a systematic review and meta-analysis / L. Marques-Silva, M. Areia, L. Elvas, M. Dinis-Ribeiro // Eur J Gastroenterol Hepatol. - 2014, Apr. - Vol. 26(4). - P. 378-387.

234. Prevalence of H. pylori infection and atrophic gastritis in a population-based screening with serum biomarker panel (GastroPanel®) in St. Petersburg / L.D. Roman, R. Lukyanchuk, O.A. Sablin [et al.] // Anticancer Res. - 2016, Aug. - Vol. 36(8). - P. 4129-4138.

235. Proliferative and apoptotic effects of gastric epithelial cells induced by coccoid Helicobacter pylori / N. Li, L. Han, J. Chen [et al.] // J Basic Microbiol. - 2013, Feb. - Vol. 53(2). - P. 147-155.

236. Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats / B.D. Tang, Z.R. Zeng, P.J. Hu [et al.] // Ai Zheng. - 2006, Oct. - Vol. 25(10). - P. 1205-1209.

237. Randomized double-blind clinical trial of Moluodan for the treatment of chronic atrophic gastritis with dysplasia / X.D. Tang, L.Y. Zhou, S.T. Zhang [et al.] // Chin J Integr Med. - 2016, Jan. - Vol. 22(1). - P. 9-18.

238. Rare Helicobacter pylori virulence genotypes in Bhutan / O. Matsunari, M. Miftahussurur, S. Shiota [et al.] // Sci Rep. - 2016, Mar. - N 6. - P. 22584.

239. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers / L. Agreus, E.J. Kuipers, L. Kupcinskas [et al.] // Scand J Gastroenterol. - 2012, Feb. - Vol. 47(2). - P. 136-147.

240. Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications / Chinese rheumatism data center; Chinese systemic lupus erythematosus treatment and research group // Zhonghua Nei Ke Za Zhi. - 2017, Jan. - Vol. 56(1). - P. 81-85.

241. Regular aspirin use and stomach cancer risk in China / Y. Wang, C. Shen, J. Ge [et al.] // Eur J Surg Oncol. - 2015, Jun. - Vol. 41(6). - P. 801-804.

242. Resveratrol: A potential challenger against gastric cancer / A. Zulueta, A. Caretti, P. Signorelli, R. Ghidoni // World J Gastroenterol. - 2015, Oct. - Vol. 21(37). - P. 10636-10643.

243. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors / M. Battistella, M. Mamdami, D. Juurlink // Arch. Intern. Med. - 2015. - Vol. 165. - P. 189-192.

244. Roth S.H. Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety / S.H. Roth // Clin Interv Aging. - 2011. - N 6. - P. 125-131.

245. Satoh H. Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats / H. Satoh, K. Amagase, K. Takeuchi // J Pharmacol Exp Ther. - 2014, Feb. - Vol. 348(2). - P. 227-35.

246. Scanzello C.R. The role of synovitis in osteoarthritis pathogenesis / C.R. Scanzello, S.R. Goldring // Bone. - 2012. - Vol. 51(2). - Р. 249-257.

247. Screening and surveillance for gastric cancer in the United States: Is it needed? / G.H. Kim, P.S. Liang, S.J. Bang, J.H. Hwang // Gastrointest Endosc. - 2016, Jul. - Vol. 84(1). - P. 18-28.

248. Secondary prevention of epidemic gastric cancer in the model of Helicobacter pylori-associated gastritis / M. Pizzi, D. Saraggi, M. Fassan [et al.] // Dig Dis. - 2014. - Vol. 32(3). - P. 265-274.

249. Seyed Mirzaei S.M. Prevalence of Helicobacter pylori-negative, non-steroidal anti-inflammatory drug related peptic ulcer disease in patients referred to Afzalipour hospital / S.M. Seyed Mirzaei, M.J. Zahedi, S. Shafiei Pour // Middle East J Dig Dis. - 2015, Oct. - Vol. 7(4). - P. 241-244.

250. Shiotani A. Eradication of gastric cancer is now both possible and practical / A. Shiotani, P. Cen, D.Y. Graham // Semin Cancer Biol. - 2013, Dec. - Vol. 23(6 Pt B) - P. 492-501.

251. Shirinskaia N.V. NSAID-gastropathy and Helicobacter pylori: more questions than answers / N.V. Shirinskaia, V.A. Akhmedov // Eksp Klin Gastroenterol. - 2010. - Vol. (9). - P. 116-120.

252. Sibony M. Recent advances in Helicobacter pylori pathogenesis / M. Sibony, N.L. Jones // Curr Opin Gastroenterol. - 2012, Jan. - Vol. 28(1). - P. 30-35.

253. Sipponen P. Chronic gastritis / P. Sipponen, H. Maaroos // Scand J Gastroenterol. - 2015, Jun. - Vol. 50(6). - P. 657-667.

254. Sokic-Milutinovic A. Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study / A. Sokic-Milutinovic, M. Krstic, B. Rozer-Smolovic // Dig Dis Sci. - 2010, Oct. - Vol. 55(10). - P. 2887-2892.

255. Successful eradication therapy for Helicobacter pylori-positive atrophic gastritis at the sixth attempt: a case report / R. Deguchi, K. Shiraishi, Y. Arase // Tokai J Exp Clin Med. - 2016, Dec. - Vol. 41(4). - P. 233-235.

256. Surveillance of patients with gastric precancerous conditions / J. Lage, N. Uedo, M. Dinis-Ribeiro, K. Yao // Best Pract Res Clin Gastroenterol. - 2016, Dec. - Vol. 30(6). - P. 913-922.

257. Syrjanen K. A panel of serum biomarkers (GastroPanel®) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis / K. Syrjanen // Anticancer Res. - 2016, Oct. - Vol. 36(10). - P. 5133-5144.

258. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility / K. Takeuchi // World J Gastroenterol. - 2012, May. - Vol. 18(18). - P. 2147-2160.

259. Ten-year prospective follow-up study on the relationship between Helicobacter pylori infection and progression of atrophic gastritis particularly assessed by endoscopic findings / N. Sakaki, H. Kozava, N. Egava [et al.] // Aliment. Pharmacol. Ther. - 2009. - Vol. 16. - P. 198-203.

260. The effect of Helicobacter pylori eradication on chronic gastritis / M. Kodama, K. Murakami, T. Okimoto, T. Fujioka // Nihon Rinsho. - 2013, Aug. - Vol. 71(8). - P. 1442-1448.

261. The genetic diversity of Helicobacter pylori virulence genes is not associated with gastric atrophy progression / M. Kita, K. Yokota, H. Okada [et al.] // Acta Med Okayama. - 2013. - N 67(2). - P. 93-98.

262. The orientation of the gastric biopsy specimen for the gastric atrophy assessment is important / B. Cotruta, G. Becheanu, R. Iacob, C. Gheorghe // J Gastrointestin Liver Dis. - 2016, Mar. - Vol. 25(1). - P. 123-124.

263. The prevalence of gastric intestinal metaplasia and distribution of Helicobacter pylori infection, atrophy, dysplasia, and cancer in its subtypes / S. Olmez, M. Aslan, R. Erten [et al.] // Gastroenterol Res Pract. - 2015. - N 2015. - P. 434039.

264. The prevalence of Helicobacter pylori infection decreases with older age in atrophic gastritis / S. Chen, L. Ying, M. Kong [et al.] // Gastroenterol Res Pract. - 2013, Sep.

265. Time trends in Helicobacter pylori infection and atrophic gastritis over 40 years in Japan / T. Kamada, K. Haruma, M. Ito [et al.] // Helicobacter. - 2015, Jun. - Vol. 20(3). - Р. 192-198.

266. Time trends of the impact of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs on peptic ulcer bleeding in Japanese patients / T. Nagasue, S. Nakamura, S. Kochi [et al.] // Digestion. - 2015. - Vol. 91(1). - P. 37-41.

267. Trujillo E. Genotyping of Helicobacter pylori virulence factors vacA and cagA in individuals from two regions in Colombia with opposing risk for gastric cancer/ Trujillo E., Martнnez T., Bravo M.M. // Biomedica. - 2014, Oct-Dec. - N 34(4). - P. 567-573.

268. Tytgat G.N. Etiopathogenetic principles and peptic ulcer disease classification / G.N. Tytgat // Dig Dis. - 2011. - N 29(5). - P. 454-458.

269. Tzourmakliotis D. Clinical significance of cytotoxin-associated gene A status of Helicobacter pylori among non-steroidal anti-inflammatory drug users with peptic ulcer bleeding: a multicenter case-control study / D. Tzourmakliotis, M. Economou, S. Manolakopolos // Scand. J. Gastroenterol. - 2004. - Vol. 39. - P. 1180-1185.

270. Valkhoff V.E. Risk factors for gastrointestinal bleeding associated with low-dose aspirin / V.E. Valkhoff, M.C. Sturkenboom, E.J. Kuipers // Best Pract Res Clin Gastroenterol. - 2012, Apr. - Vol. 26(2). - P. 125-140.

271. Vane J. The mechanism of action of anti-inflammatory drugs / J. Vane // Thromb Res. - 2003, Jun. - Vol. 110(5-6). - P. 255-258.

272. Vane J.R. The mechanism of action of aspirin / J.R. Vane, R.M. Botting // Int J Clin Pract Suppl. - 2003, Apr. - N 135. - P. 2.

273. Venerito M. Interaction of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in gastric and duodenal ulcers / M. Venerito, P. Malfertheiner // Helicobacter. - 2010, Aug. - Vol. 15(4). - P. 239-250.

274. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy / J.L. Wallace // World J Gastroenterol. - 2013, Mar. - Vol. 19(12). - P. 1861-1876.

275. Wolle K. Treatment of Helicobacter pylori / K. Wolle, P. Malfertheiner // Best Pract Res Clin Gastroenterol. - 2013. - N 21. - P. 315-324.

276. Yap P.R. Non-steroidal anti-inflammatory drugs (NSAIDs) induced dyspepsia / P.R. Yap, K.L. Goh // Curr Pharm Des. - 2015. - Vol. 21(35). - P. 5073-5081.

277. Yoon H. Diagnosis and management of high risk group for gastric cancer / H. Yoon, N. Kim // Gut Liver. - 2015, Jan. - Vol. 9(1) - Р. 5-17.

278. Zhang W. An update on Helicobacter pylori as the cause of gastric cancer / W. Zhang, H. Lu, D.Y. Graham // Gastrointest Tumors. - 2014, Aug. - Vol. 1(3) - P. 155-165.

279. Zhang Y. Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China / Y. Zhang, K.F. Pan, L. Zhang // Carcinogenesis. - 2015, Dec. - Vol. 36(12). - P. 572-579.

280. Zhao Y.Q. Effects of broth culture filtrate protein of VacA+ Helicobacter pylori on the proliferation and apoptosis of gastric epithelial cells / Y.Q. Zhao, T. Guo, J.M. Qian // Chin Med J (Engl). - 2013. - Vol. 126(11). - P. 2168-2173.

ПЕРЕЛІК УМОВНИХ СКОРОЧЕНЬ

Размещено на Allbest.ru